Skip to main content

Dubow Adam's Form 4 filing

Day One Biopharmaceuticals, Inc. (DAWN) · filed May 17, 2024

Accession no.
0001415889-24-013614
Filed
May 17, 2024
Trade date
May 15-16, 2024
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market sales total $52.3K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Dubow AdamCIK 0001744507Officer (GENERAL COUNSEL)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 15, 2024Common StockMOption exerciseAcquired+2,962––19,547Direct
May 15, 2024Common StockMOption exerciseAcquired+1,750––21,297Direct
May 15, 2024Common StockMOption exerciseAcquired+3,687––24,984Direct
May 16, 2024Common StockSSaleDisposed−3,253$16.08−$52,308.2421,731Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 15, 2024Common StockMOption exerciseDisposed−2,962$0.00$029,626Direct
May 15, 2024Common StockMOption exerciseDisposed−1,750$0.00$017,500Direct
May 15, 2024Common StockMOption exerciseDisposed−3,687$0.00$051,626Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)